Q1 PA&E Roundtable Event: Patient Stories Without a Fixed Address
Exclusive to T2B Pro and Student members.
If you're not part of Ticket to Biotech, confirm you're eligible, and join as a Pro or Student member before registering for this event:
T2B Intake Form
***If you do not receive your event confirmation within 1 business day of RSVPing (above), check your email spam folder. The automated Luma email includes the Zoom info and cal invite.***
PATIENT STORIES WITHOUT A FIXED ADDRESS
This inaugural panel from T2B’s Patient Advocacy & Engagement Roundtable will focus on the vital role of patient advocacy in shaping communications within the life sciences industry. This session will bring together professionals working across diverse organizational structures, whether patient advocacy is embedded in research, medical, commercial, corporate affairs, or operates as an independently structured team.
Together, we will explore how communicators partner with advocacy colleagues to gather patient insights and stories that strengthen internal and external communications, ensuring the patient voice is reflected thoughtfully and responsibly in our narratives.
Why Attend:
Understand how different advocacy structures influence communications strategy and storytelling.
Learn how communicators can effectively partner with research, medical, commercial, and advocacy teams.
Walk away with approaches for responsibly integrating patient insights into messaging, campaigns, and leadership communications.
Connect with fellow communicators navigating similar structural and storytelling challenges.
Featuring:
Stephanie Kenney, Senior Vice President of Corporate Development, Avidity Biosciences
Dr. Anthony Yanni, Founder & CEO, Lucid Health Solutions
Panel moderator:
Jeff Sears, T2B PA&E Roundtable Member and Global Head, Strategy & Operations, Communications and Investor Relations, Astellas U.S.
MEET OUR GUEST SPEAKERS
Stephanie Kenney, Senior Vice President of Corporate Development, Avidity Biosciences
Stephanie Kenney has extensive experience in corporate communications and public relations within the healthcare and technology sectors. Beginning as an Account Executive at The MWW Group, Stephanie progressed through roles at Dorland Global Health Communications, where responsibilities included managing multi-disciplinary campaigns and contributing to significant budget management. At AstraZeneca, positions ranged from Director of Corporate Affairs to US Head of Corporate Affairs for Respiratory and Immunology, emphasizing the strategic management of brand communications and stakeholder engagement. Following contributions to Hansa Biopharma as Vice President of Global Corporate Affairs, Stephanie currently serves as Senior Vice President of Corporate Development at Avidity Biosciences, showcasing a robust trajectory in corporate strategy and communications since earning a Bachelor of Science in Mass Communications with a focus on Public Relations from Mansfield University.
Dr. Anthony Yanni, Founder & CEO, Lucid Health Solutions
Dr. Anthony Yanni, a veteran healthcare professional and pharma executive, is a transformative leader known for advocating and executing patient centricity in global healthcare practices. In his most recent industry role as Senior Vice President and Global Head of Patient Centricity at Astellas Pharma, Anthony was pivotal in integrating patient perspectives and real-world needs into pharmaceutical innovation, development, and delivery.
A medical practitioner for 15 years, he held crucial roles such as Chief Medical Officer and Chief of Internal Medicine in a Northeastern US health system. His clinical experience led him to recognize the significance of focusing on the patient, not just the disease, resulting in truly meaningful innovations.
In 2024, Anthony published his first book, A Bandana and A Bluebird – The Path to a Patient Centric Healthcare System in which he details, through patient vignettes and programmatic examples, the progress made toward achieving a more patient focused system of care as well as the challenges that remain.